WB;IHC;IF;ELISA

18kD

The antiserum was produced against synthesized peptide derived from human p14 ARF. AA range:71-120

p14 Polyclonal Antibody detects endogenous levels of p14 protein.

Polyclonal, Rabbit,IgG

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Western Blot: 1/500 - 1/2000. Immunohistochemistry: 1/100 - 1/300. Immunofluorescence: 1/200 - 1/1000. ELISA: 1/20000. Not yet tested in other applications.

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

1 mg/ml

CDKN2A generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by CDKN2A, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. CDKN2A is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene.

CDKN2A

Cyclin-dependent kinase inhibitor 2A isoform 4

p14

CDKN2A; CDKN2; MLM; Cyclin-dependent kinase inhibitor 2A; isoform 4; p14ARF; p19ARF

1029

Q8N726

Q64364

Nucleus, nucleolus . Nucleus, nucleoplasm .; [Isoform smARF]: Mitochondrion .

-20°C/1 year